CLINICAL TRIAL: IMPACTS TRIAL: INVESTIGATION OF THE MODULATION OF PHOSPHOLIPASE

临床试验：影响试验：磷脂酶调节的研究

• 批准号: 7716901
• 负责人: Kenneth I Ataga
• 金额: $ 0.01万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-02 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7716901
• 关键词: Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Development; Dose; Double-Blind Method; Fever; Funding; Grant; Infusion procedures; Institution; Investigation; Patients; Phospholipase; Placebo Control; Prevention; Randomized; Research; Research Personnel; Resources; Risk; Serum; Sickle Cell Anemia; Source; United States National Institutes of Health; acute chest syndrome; base; cohort

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a double-blind randomized, parallel group, placebo-controlled dose escalation study (2 cohorts) of Varespladib Infusion [A-001] for the prevention of acute chest syndrome in patients with sickle cell disease who are at-risk for development of acute chest syndrome (ACS) based on the combination of vaso-occlusive crisis, fever, and elevated serum sPLA2 concentration.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这是一项双盲随机、平行分组、安慰剂对照的剂量递增研究(2个队列)。 Varespladib注射[A-001]用于预防镰状细胞疾病患者的急性胸部综合征，这些患者有发展为急性胸部综合征(ACS)的风险，其基础是血管闭塞危象、发热和血清sPLA2浓度升高。